RIO DE JANEIRO, BRAZIL - Preliminary results of a research conducted by the Vebra Covid-19 group released on Wednesday, March 7, pointed out that CoronaVac - the most used vaccine in Brazil today - is 50% effective against symptomatic cases of infection by the P.1 variant, the one from Manaus, also called the Brazilian variant. The positive results are observed 14 days after the first dose of the immunization.
The study involved 67,718 health workers in the capital of the state of Amazonas, where the P.1 mutation is prevalent, says the researchers' statement. The same material points out that . . .